AEON Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	9.95	9.95	13.68	11.15	0
Research & Development	13.24	13.24	34.75	25.73	0
Other Operating Expenses	348	348	0	28.97	0
Operating Expenses	371.19	371.19	48.43	65.85	0
Operating Income	-371.19	-371.19	-48.43	-65.85	-0
Other Expense / Income	-47.24	-47.24	4.13	-10.21	-
Pretax Income	-323.95	-323.95	-52.56	-55.64	-0
Net Income	-323.95	-323.95	-52.56	-55.64	-0
Shares Outstanding (Basic)	37	37	139	126	6
Shares Outstanding (Diluted)	37	37	139	126	6
Shares Change	-73.24%	-73.24%	9.98%	2004.21%	-
EPS (Basic)	-8.72	-8.72	-0.38	-0.44	-
EPS (Diluted)	-8.72	-8.72	-0.38	-0.44	-
Free Cash Flow	-26.08	-26.08	-35.89	-28.6	0
Free Cash Flow Per Share	-0.70	-0.70	-0.26	-0.23	-
EBITDA	-323.91	-323.91	-52.49	-55.63	-0
Depreciation & Amortization	0.05	0.05	0.07	0	0
EBIT	-323.95	-323.95	-52.56	-55.64	-0

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).